Skip to main content
Search
Main content
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration

Authors

Katherine R Birditt, Kalliopi Mavromati, Peter Swann, Terence Quinn, Atticus H Hainsworth, Lynne Hughes, John T O'Brien, William McEwan, Maura Malpetti

Abstract

Alzheimers Dement. 2026 Jul;22(7):e71642. doi: 10.1002/alz.71642.

ABSTRACT

INTRODUCTION: Immune signaling alterations have been implicated in Alzheimer's disease (AD) pathophysiology, but their heterogeneity across the disease continuum in real-world cohorts is poorly characterized, limiting the development of stratified immunomodulatory approaches.

METHODS: In a diverse multicenter cohort (BioHermes) of 176 amyloid-positive individuals with AD/mild cognitive impairment (MCI) and 173 age and sex-matched controls, principal component analysis was performed on Luminex-measured plasma cytokines to derive inflammatory signatures, and their direct/indirect associations with cognition and neurodegeneration.

RESULTS: Two components were identified. Proinflammatory Component 2 was elevated in AD/MCI and in Black/African American participants, and strongly associated with poorer cognition (independently of neurofilament light [NfL], phosphorylated tau 217 [p-tau217], and glial fibrillary acidic protein [GFAP]). Inflammatory Component 1 showed an indirect association with cognition, mediated by neurodegeneration (plasma NfL).

DISCUSSION: Plasma inflammation profiles were associated with poorer cognition via direct and neurodegeneration-mediated pathways, supporting their potential use as stratification markers in AD therapeutics.

PMID:42363728 | DOI:10.1002/alz.71642

UK DRI Authors

Dr Maura Malpetti

Emerging Leader

Using specialist brain scans and novel blood tests to measure inflammation and accelerate the development of new treatments

Dr Maura Malpetti